Clinical and molecular pharmacologic characteristics of adenosine-induced vasodilation

Clinical Pharmacology and Therapeutics

Volumn 75, Issue 3, 2004, Pages 137-139

  Biaggioni, Italo ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DEAMINASE INHIBITOR; DIPYRIDAMOLE; GLIBENCLAMIDE; POTASSIUM CHANNEL;

ANTIARRHYTHMIC ACTIVITY; ARTERIOLE; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DILATATION; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESPONSE; DRUG SENSITIVITY; ENDOTHELIUM CELL; HUMAN; NONHUMAN; NOTE; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER; SUPRAVENTRICULAR TACHYCARDIA; SYMPATHETIC TONE; TREATMENT INDICATION; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE; VASODILATATION;

ADENOSINE; ANIMALS; HEART DISEASES; HUMANS; VASODILATION;

EID: 1542346410     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2003.09.017     Document Type: Note

References (12)

1. Drury A.W., Szent-Györgyi A. The physiological activity of adenosine compounds with a special reference to their action upon the mammalian heart. J Physiol. 68:1929;213-237.
2. Biaggioni I., Killian T.J., Mosqueda-Garcia R., Robertson R.M., Robertson D. Adenosine increases sympathetic nerve traffic in humans. Circulation. 83:1991;1668-1675.
3. Biaggioni I., Olafsson B., Robertson R.M., Hollister A.S., Robertson D. Cardiovascular and respiratory effects of adenosine in conscious man evidence for chemoreceptor activation. Circ Res. 61:1987;779-786.
4. Biaggioni I., Onrot J., Kincaid D., Hollister A.S., Robertson D. Cardiovascular effects of adenosine infusion in man and their modulation by dipyridamole. Life Sci. 39:1986;2229-2236.
5. Gorman M.W., Bassingthwaighte J.B., Olsson R.A., Sparks H.V. Endothelial cell uptake of adenosine in canine skeletal muscle. Am J Physiol. 250:(3 Pt 2):1986;H482-489.
6. Gamboa A., Ertl A.C., Costa F., Farley G., Manier M.L., Hachey D.L., et al. Blockade of nucleoside transport is required for delivery of intraarterial adenosine into the interstitium relevance to therapeutic preconditioning in humans. Circulation. 108:2003;2631-2635.
7. Smits P., Williams S.B., Lipson D.E., Banitt P., Rongen G.A., Creager M.A. Endothelial release of nitric oxide contributes to the vasodilator effect of adenosine in humans. Circulation. 92:1995;2135-2141.
8. Quyyumi A.A., Dakak N., Andrews N.P., Gilligan D.M., Panza J.A., Cannon R.O. Contribution of nitric oxide to metabolic coronary vasodilation in the human heart. Circulation. 92:1995;320-326.
9. Shiode N., Morishima N., Nakayama K., Yamagata T., Matsuura H., Kajiyama G. Flow-mediated vasodilation of human epicardial coronary arteries effect of inhibition of nitric oxide synthesis. J Am Coll Cardiol. 27:1996;304-310.
10. Costa F., Biaggioni I. Role of nitric oxide in adenosine-induced vasodilation in humans. Hypertension. 31:1998;1061-1064.
11. Bijlstra P, van Ginneken EEM, Huls M, van Dijk R, Smits P, Rongen GA. Glyburide inhibits dipyridamole-induced forearm vasodilation but not adenosine-induced forearm vasodilation. Clin Pharmacol Ther 2004;75:147-56
12. Hein T.W., Kuo L. cAMP-independent dilation of coronary arterioles to adenosine role of nitric oxide, G proteins, and K(ATP) channels. Circ Res. 85:1999;634-642.